These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

218 related items for PubMed ID: 38277031

  • 1. Different bone health progression patterns and early-stage risk marker in glucocorticoid-treated ambulatory Duchenne muscular dystrophy.
    Zhou L, Zhou H, Xu H, Sun X, Chen X, Fan P, Cai X, Wang Q.
    Osteoporos Int; 2024 Jun; 35(6):997-1005. PubMed ID: 38277031
    [Abstract] [Full Text] [Related]

  • 2. Bone health measures in glucocorticoid-treated ambulatory boys with Duchenne muscular dystrophy.
    Tian C, Wong BL, Hornung L, Khoury JC, Miller L, Bange J, Rybalsky I, Rutter MM.
    Neuromuscul Disord; 2016 Nov; 26(11):760-767. PubMed ID: 27614576
    [Abstract] [Full Text] [Related]

  • 3. Risk factors associated with prevalent vertebral fractures in Duchenne muscular dystrophy.
    Phung K, McAdam L, Ma J, McMillan HJ, Jackowski S, Scharke M, Matzinger MA, Shenouda N, Koujok K, Jaremko JL, Smit K, Walker S, Hartigan C, Khan N, Konji VN, MacLeay L, Page M, Sykes E, Robinson ME, Alos N, Cummings EA, Ho J, Sbrocchi AM, Stein R, Saleh D, Craven BC, Dang UJ, Siminoski K, Rauch F, Ward LM.
    Osteoporos Int; 2023 Jan; 34(1):147-160. PubMed ID: 36342539
    [Abstract] [Full Text] [Related]

  • 4. The time to and determinants of first fractures in boys with Duchenne muscular dystrophy.
    Ma J, McMillan HJ, Karagüzel G, Goodin C, Wasson J, Matzinger MA, DesClouds P, Cram D, Page M, Konji VN, Lentle B, Ward LM.
    Osteoporos Int; 2017 Feb; 28(2):597-608. PubMed ID: 27774565
    [Abstract] [Full Text] [Related]

  • 5. Bone density and bone health alteration in boys with Duchenne Muscular Dystrophy: a prospective observational study.
    Suthar R, Reddy BVC, Malviya M, Sirari T, Attri SV, Patial A, Tageja M, Didwal G, Khandelwal NK, Saini AG, Saini L, Sahu JK, Dayal D, Sankhyan N.
    J Pediatr Endocrinol Metab; 2021 May 26; 34(5):573-581. PubMed ID: 33838091
    [Abstract] [Full Text] [Related]

  • 6. Effectiveness of Neridronate in the Management of Bone Loss in Patients with Duchenne Muscular Dystrophy: Results from a Pilot Study.
    Moretti A, Liguori S, Paoletta M, Gimigliano F, Iolascon G.
    Adv Ther; 2022 Jul 26; 39(7):3308-3315. PubMed ID: 35614293
    [Abstract] [Full Text] [Related]

  • 7. Bone Mineral Density Assessment by Quantitative Computed Tomography in Glucocorticoid-Treated Boys With Duchenne Muscular Dystrophy: A Linear Mixed-Effects Modeling Approach.
    Liu C, Yang DD, Zhang L, Lei XG, Jia FL, Liao Y, Chen XJ, Ning G, Luo W, Qu HB.
    Front Endocrinol (Lausanne); 2022 Jul 26; 13():860413. PubMed ID: 35399923
    [Abstract] [Full Text] [Related]

  • 8. Reduced bone mineral density in adolescents with Duchenne Muscular Dystrophy (DMD) and scoliosis.
    Tsaknakis K, Jäckle K, Lüders KA, Lorenz HM, Braunschweig L, Hell AK.
    Osteoporos Int; 2022 Sep 26; 33(9):2011-2018. PubMed ID: 35583603
    [Abstract] [Full Text] [Related]

  • 9. Growth, bone health & ambulatory status of boys with DMD treated with daily vs. intermittent oral glucocorticoid regimen.
    Crabtree NJ, Adams JE, Padidela R, Shaw NJ, Högler W, Roper H, Hughes I, Daniel A, Mughal MZ.
    Bone; 2018 Nov 26; 116():181-186. PubMed ID: 30055340
    [Abstract] [Full Text] [Related]

  • 10. Interventions to prevent and treat corticosteroid-induced osteoporosis and prevent osteoporotic fractures in Duchenne muscular dystrophy.
    Bell JM, Shields MD, Watters J, Hamilton A, Beringer T, Elliott M, Quinlivan R, Tirupathi S, Blackwood B.
    Cochrane Database Syst Rev; 2017 Jan 24; 1(1):CD010899. PubMed ID: 28117876
    [Abstract] [Full Text] [Related]

  • 11. Fractures and Linear Growth in a Nationwide Cohort of Boys With Duchenne Muscular Dystrophy With and Without Glucocorticoid Treatment: Results From the UK NorthStar Database.
    Joseph S, Wang C, Bushby K, Guglieri M, Horrocks I, Straub V, Ahmed SF, Wong SC, UK NorthStar Clinical Network.
    JAMA Neurol; 2019 Jun 01; 76(6):701-709. PubMed ID: 30855644
    [Abstract] [Full Text] [Related]

  • 12. Timing of low bone mineral density and predictors of bone mineral density trajectory in children on long-term warfarin: a longitudinal study.
    Avila ML, Pullenayegum E, Williams S, Shammas A, Stimec J, Sochett E, Marr K, Brandão LR.
    Osteoporos Int; 2016 Apr 01; 27(4):1547-1557. PubMed ID: 26572757
    [Abstract] [Full Text] [Related]

  • 13. The use of intravenous bisphosphonate therapy to treat vertebral fractures due to osteoporosis among boys with Duchenne muscular dystrophy.
    Sbrocchi AM, Rauch F, Jacob P, McCormick A, McMillan HJ, Matzinger MA, Ward LM.
    Osteoporos Int; 2012 Nov 01; 23(11):2703-11. PubMed ID: 22297733
    [Abstract] [Full Text] [Related]

  • 14. Oral bisphosphonate treatment in patients with Duchenne muscular dystrophy on long term glucocorticoid therapy.
    Tian C, Wong BL, Hornung L, Khoury JC, Rybalsky I, Shellenbarger KC, Rutter MM.
    Neuromuscul Disord; 2020 Jul 01; 30(7):599-610. PubMed ID: 32680651
    [Abstract] [Full Text] [Related]

  • 15. Skeletal disproportion in glucocorticoid-treated boys with Duchenne muscular dystrophy.
    Kao KT, Joseph S, Capaldi N, Brown S, Di Marco M, Dunne J, Horrocks I, Shepherd S, Ahmed SF, Wong SC.
    Eur J Pediatr; 2019 May 01; 178(5):633-640. PubMed ID: 30762116
    [Abstract] [Full Text] [Related]

  • 16. Safety and efficacy of teriparatide treatment for severe osteoporosis in patients with Duchenne muscular dystrophy.
    Nasomyont N, Keefe C, Tian C, Hornung L, Khoury J, Tilden JC, Hochwalt P, Jackson E, Rybalsky I, Wong BL, Rutter MM.
    Osteoporos Int; 2020 Dec 01; 31(12):2449-2459. PubMed ID: 32676823
    [Abstract] [Full Text] [Related]

  • 17. Can radial bone mineral density predict spinal bone mineral density in patients with advanced Duchenne muscular dystrophy?
    Kim E, Cho HE, Jung JH, Lee JW, Choi WA, Kang SW.
    Medicine (Baltimore); 2018 Oct 01; 97(40):e12303. PubMed ID: 30290594
    [Abstract] [Full Text] [Related]

  • 18. Risk Factors Associated with Incident Vertebral Fractures in Steroid-treated Males with Duchenne Muscular Dystrophy.
    Phung K, McAdam L, Ma J, McMillan HJ, Jackowski S, Scharke M, Matzinger MA, Shenouda N, Koujok K, Jaremko JL, Wilson N, Walker S, Hartigan C, Khan N, Page M, Robinson ME, Saleh DS, Smit K, Rauch F, Siminoski K, Ward LM.
    J Clin Endocrinol Metab; 2024 Jan 18; 109(2):536-548. PubMed ID: 37610420
    [Abstract] [Full Text] [Related]

  • 19. Low bone density and bone metabolism alterations in Duchenne muscular dystrophy: response to calcium and vitamin D treatment.
    Bianchi ML, Morandi L, Andreucci E, Vai S, Frasunkiewicz J, Cottafava R.
    Osteoporos Int; 2011 Feb 18; 22(2):529-39. PubMed ID: 20458570
    [Abstract] [Full Text] [Related]

  • 20. Effect of Testosterone Treatment for Delayed Puberty in Duchenne Muscular Dystrophy.
    Lee SL, Lim A, Munns C, Simm PJ, Zacharin M.
    Horm Res Paediatr; 2020 Feb 18; 93(2):108-118. PubMed ID: 32610327
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.